Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.31 |
| ▸ | PEPD | P12955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL1615496 | 0.96 | CA2 (0.46) | CA2CA1CA9MEN1LMNA | |
| Phosphoric Acid SCHEMBL718179 | 0.96 | CA2 (0.46) | CA2CA1CA9MEN1LMNA | |
| Phosphoric Acid SCHEMBL721347 | 0.96 | CA2 (0.46) | CA2CA1CA9MEN1LMNA | |
| Phosphoric Acid SCHEMBL9078842 | 0.91 | CA2 (0.50) | CA2CA1CA9MEN1LMNA | |
| Phosphoric Acid SCHEMBL9449859 | 0.91 | CA2 (0.50) | CA2CA1CA9MEN1LMNA | |
| Phosphoric Acid SCHEMBL6112781 | 0.91 | CA2 (0.50) | CA2CA1CA9MEN1LMNA | |
| Phosphoric Acid SCHEMBL10515585 | 0.91 | CA2 (0.50) | CA2CA1CA9MEN1LMNA | |
| Phosphoric Acid SCHEMBL6112776 | 0.91 | CA2 (0.50) | CA2CA1CA9MEN1LMNA | |
| Phosphoric Acid SCHEMBL345048 | 0.91 | CA2 (0.50) | CA2CA1CA9MEN1LMNA | |
| Phosphoric Acid SCHEMBL28048398 | 0.91 | CA2 (0.50) | CA2CA1CA9MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046262-A1 | Pasty Insert Material for Widening of Gingival Sulcus and Use Thereof | KETTENBACH GMBH & CO. KG (DE) | 2011-02-24 | — | — | US | claimed |
| US-20070218018-A1 | SENSITIVITY RELIEF GEL | DISCUS DENTAL IMPRESSIONS, INC. (US) | 2007-09-20 | — | — | US | claimed |
| US-5534244-A | APPLYING TO TEETH COMPOUNDS WHICH WILL FORM STRONTIUM CONTAINING APATITE, DENTISTRY | ADA FOUNDATION | 1996-07-09 | — | — | US | claimed |
| US-20200038300-A1 | ORAL CARE FORMULATION SYSTEM PROVIDING AMORPHOUS CALCIUM PHOSPHATE | KONINKLIJKE PHILIPS NV (NL) | 2020-02-06 | — | — | US | disclosed |
| EP-3166692-B1 | ORAL CARE FORMULATION SYSTEM PROVIDING AMORPHOUS CALCIUM PHOSPHATE | KONINKLIJKE PHILIPS NV (NL) | 2019-11-06 | — | — | EP | disclosed |
| US-20170157003-A1 | ORAL CARE FORMULATION SYSTEM PROVIDING AMORPHOUS CALCIUM PHOSPHATE | KONINKLIJKE PHILIPS N.V. (NL) | 2017-06-08 | — | — | US | disclosed |
| EP-3166692-A1 | ORAL CARE FORMULATION SYSTEM PROVIDING AMORPHOUS CALCIUM PHOSPHATE | Koninklijke Philips N.V. (NL) | 2017-05-17 | — | — | EP | disclosed |
| US-20160279039-A1 | Whitening system capable of delivering effective whitening action | GINIGER MARTIN S (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160271022-A1 | Foaming Compositions and Methods | GINIGER MARTIN S (US) | 2016-09-22 | — | — | US | disclosed |
| US-9289362-B2 | Foaming compositions and methods | GRINRX CORPORATION | 2016-03-22 | — | — | US | disclosed |
| US-9271902-B2 | Whitening system capable of delivering effective whitening action | GRINRX CORPORATION | 2016-03-01 | — | — | US | disclosed |
| WO-2006073559-A1 | TWO-COMPONENT DENTAL WHITENING COMPOSITIONS | DISCUS DENTAL IMPRESSIONS INC (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060115437-A1 | Dental whitening compositions | DISCUS DENTAL, LLC | 2006-06-01 | — | — | US | disclosed |
| WO-2006053207-A2 | DENTAL WHITENING SYSTEMS COMPRISING TRANSITION METAL SALT ACTIVATOR | DISCUS DENTAL IMPRESSIONS, INC (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060099155-A1 | Dental whitening systems | DISCUS DENTAL IMPRESSIONS, INC. | 2006-05-11 | — | — | US | disclosed |
| US-20060099156-A1 | Dental whitening compositions | DISCUS DENTAL IMPRESSIONS, INC | 2006-05-11 | — | — | US | disclosed |
| WO-2006014365-A2 | DENTAL COMPOSITIONS WITH SENSITIVITY RELIEF | DISCUS DENTAL IMPRESSIONS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060008424-A1 | Dental compositions with sensitivity relief | DEN-MAT HOLDINGS, LLC | 2006-01-12 | — | — | US | disclosed |
| US-5534244-A | APPLYING TO TEETH COMPOUNDS WHICH WILL FORM STRONTIUM CONTAINING APATITE, DENTISTRY | ADA FOUNDATION | 1996-07-09 | — | — | US | disclosed |
| US-5534244-A | APPLYING TO TEETH COMPOUNDS WHICH WILL FORM STRONTIUM CONTAINING APATITE, DENTISTRY | ADA FOUNDATION | 1996-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060099155-A1 | Dental whitening systems | MGST3, GSS, TXN | CA2 420/4885CA1 1135/4885CA9 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.